AU Stock MarketDetailed Quotes

CMB Cambium Bio Ltd

Watchlist
  • 0.230
  • +0.005+2.22%
20min DelayTrading Apr 29 12:18 AET
4.21MMarket Cap-0.43P/E (Static)

About Cambium Bio Ltd Company

Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate Elate Ocular is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.

Company Profile

SymbolCMB
Company NameCambium Bio Ltd
Founded2007
MarketASX
Fiscal Year Ends06-30
Address16 Goodhope Street Paddington
CitySydney
CountryAustralia
Zip Code2021
Phone+61 1300995098
Share RegistryMUFG CORPORATE MARKETS (AU) LIMITED LIBERTY PLACE, LEVEL 41, 161 CASTLEREAGH ST, SYDNEY, NSW, AUSTRALIA, 2000 1300 554 474

Company Executives

  • Name
  • Position
  • Salary
  • Edmund Waller
  • Executive Director and Chief Scientific Officer
  • --
  • Barry George Sechos
  • Non-Executive Chairman
  • --
  • Yu-Hung Sebastian Tseng
  • Non-Executive Director
  • --
  • Terence A Walts
  • Executive Director
  • --
  • Graham Vesey
  • Executive Director
  • --

Market Insights

Warren Buffett Portfolio Warren Buffett Portfolio

Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.

Unlock Now

Discussing

2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current Show More